Holzer Phil M, SVP and Controller at Bristol-Myers Squibb (BMY), has demonstrated a clear selling bias in his insider transactions, with no recorded purchases across 24 reported trades. All activity has been concentrated in BMY, with total sales amounting to $156,370.85. The transactions, primarily executed on March 10, 2024, and March 10, 2026, involved multiple dispositions under code "F" (indicating transactions made to satisfy tax withholding obligations). The largest single sale occurred on March 10, 2024, valued at $53,359.68, followed by a $51,050.37 transaction on March 10, 2026. Smaller sales, such as $14,912.24 and $15,693.93 in 2026 and $11,295.90 and $10,058.73 in 2024, suggest periodic liquidation of shares rather than a single bulk divestment.
The absence of any buying activity and the repeated pattern of sales—particularly those tied to tax-related dispositions—indicate a consistent reduction in Holzer’s BMY holdings over time. While the transactions do not reflect open-market sales, the recurring nature of these disposals, especially in similar dollar ranges across multiple years, points to a structured approach to managing equity compensation. The lack of recent trades outside these March 2024 and 2026 filings suggests no new material changes in his position since the last reported activity. The data reveals a disciplined, albeit one-sided, approach to insider transactions without signaling broader market sentiment.
AI-assisted summary